12/19
04:05 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/14
05:49 am
etnb
89bio, Inc. (NASDAQ: ETNB) was upgraded by analysts at Raymond James to a "strong-buy" rating.
Low
Report
89bio, Inc. (NASDAQ: ETNB) was upgraded by analysts at Raymond James to a "strong-buy" rating.
12/4
01:07 pm
etnb
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Medium
Report
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
11/29
01:35 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Neutral
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/29
01:30 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26
04:14 pm
etnb
89bio to Participate in the 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]
Low
Report
89bio to Participate in the 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]
11/26
04:05 pm
etnb
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
Low
Report
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
11/15
08:10 am
etnb
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 [Yahoo! Finance]
Medium
Report
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 [Yahoo! Finance]
11/15
08:05 am
etnb
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
Medium
Report
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
11/12
11:58 pm
etnb
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
11/12
04:12 pm
etnb
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
11/12
04:01 pm
etnb
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
11/11
08:09 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Medium
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
11/8
01:45 pm
etnb
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Raymond James from $53.00 to $49.00. They now have a "strong-buy" rating on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Raymond James from $53.00 to $49.00. They now have a "strong-buy" rating on the stock.
11/7
04:05 pm
etnb
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
Medium
Report
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
11/5
04:05 pm
etnb
89bio to Participate in the UBS Global Healthcare Conference
High
Report
89bio to Participate in the UBS Global Healthcare Conference
10/15
08:30 am
etnb
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
Low
Report
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
10/11
04:05 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/30
04:05 pm
etnb
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
Low
Report
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference